JP2012131827A5 - - Google Patents

Download PDF

Info

Publication number
JP2012131827A5
JP2012131827A5 JP2012077545A JP2012077545A JP2012131827A5 JP 2012131827 A5 JP2012131827 A5 JP 2012131827A5 JP 2012077545 A JP2012077545 A JP 2012077545A JP 2012077545 A JP2012077545 A JP 2012077545A JP 2012131827 A5 JP2012131827 A5 JP 2012131827A5
Authority
JP
Japan
Prior art keywords
weight
amount
composition
desoxyascomycin
epi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012077545A
Other languages
English (en)
Other versions
JP2012131827A (ja
JP5599422B2 (ja
Filing date
Publication date
Priority claimed from GB9421612A external-priority patent/GB9421612D0/en
Priority claimed from GB9422306A external-priority patent/GB9422306D0/en
Priority claimed from GBGB9503553.1A external-priority patent/GB9503553D0/en
Application filed filed Critical
Publication of JP2012131827A publication Critical patent/JP2012131827A/ja
Publication of JP2012131827A5 publication Critical patent/JP2012131827A5/ja
Application granted granted Critical
Publication of JP5599422B2 publication Critical patent/JP5599422B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (5)

  1. 3−エピ−クロロ−33−デスオキシアスコマイシンを懸濁液中に含む、皮膚に投与するための局所用医薬組成物であって、
    a)5重量%までの量の33−エピ−クロロ−33−デスオキシアスコマイシン、
    b)20重量%までの量の濃厚剤、
    c)40重量%までの量の親水性成分、
    d)全量5重量%までの量の1個またはそれ以上の有機酸、
    e)全量5重量%までの量の1個またはそれ以上の安定化剤、
    f)90重量%までの量の水
    を含む水中油型乳剤ゲルの形である、組成物
  2. 懸濁液が、直径5から90ミクロンの33−エピ−クロロ−33−デスオキシアスコマイシンの粒子を含む、請求項1に記載の組成物。
  3. 濃厚剤が、パラフィン、蝋またはワセリンを含む、請求項1または2に記載の組成物。
  4. 親水性成分が、プロピレングリコール、セチルアルコール、ステアリルアルコールまたはオレイルアルコールを含む、請求項1〜3のいずれかに記載の組成物。
  5. 有機酸が、ソルビン酸を含む、請求項1〜4のいずれかに記載の組成物。
JP2012077545A 1994-10-26 2012-03-29 医薬組成物 Expired - Lifetime JP5599422B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9421612A GB9421612D0 (en) 1994-10-26 1994-10-26 Organic compounds
GB9421612.4 1994-10-26
GB9422306A GB9422306D0 (en) 1994-11-04 1994-11-04 Organic compounds
GB9422306.2 1994-11-04
GB9503553.1 1995-02-22
GBGB9503553.1A GB9503553D0 (en) 1995-02-22 1995-02-22 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007047216A Division JP2007145860A (ja) 1994-10-26 2007-02-27 医薬組成物

Publications (3)

Publication Number Publication Date
JP2012131827A JP2012131827A (ja) 2012-07-12
JP2012131827A5 true JP2012131827A5 (ja) 2013-05-30
JP5599422B2 JP5599422B2 (ja) 2014-10-01

Family

ID=27267447

Family Applications (3)

Application Number Title Priority Date Filing Date
JP51431096A Expired - Lifetime JP4155593B2 (ja) 1994-10-26 1995-10-26 医薬組成物
JP2007047216A Withdrawn JP2007145860A (ja) 1994-10-26 2007-02-27 医薬組成物
JP2012077545A Expired - Lifetime JP5599422B2 (ja) 1994-10-26 2012-03-29 医薬組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP51431096A Expired - Lifetime JP4155593B2 (ja) 1994-10-26 1995-10-26 医薬組成物
JP2007047216A Withdrawn JP2007145860A (ja) 1994-10-26 2007-02-27 医薬組成物

Country Status (26)

Country Link
US (1) US6352998B2 (ja)
EP (2) EP0786986B1 (ja)
JP (3) JP4155593B2 (ja)
KR (1) KR100434682B1 (ja)
CN (2) CN1089233C (ja)
AT (2) ATE214593T1 (ja)
AU (1) AU714254B2 (ja)
BR (1) BR9509530A (ja)
CA (1) CA2200966C (ja)
CY (1) CY2211B1 (ja)
CZ (1) CZ289773B6 (ja)
DE (3) DE69525957T2 (ja)
DK (2) DK1147766T3 (ja)
ES (2) ES2243369T3 (ja)
FI (2) FI119754B (ja)
GB (1) GB2308546B (ja)
HK (1) HK1053611A1 (ja)
HU (1) HU223840B1 (ja)
MX (1) MX9702699A (ja)
NO (2) NO316963B1 (ja)
NZ (2) NZ295170A (ja)
PL (1) PL184750B1 (ja)
PT (2) PT786986E (ja)
SI (1) SI0786986T1 (ja)
SK (1) SK284591B6 (ja)
WO (1) WO1996013249A1 (ja)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
CZ283516B6 (cs) * 1996-09-12 1998-04-15 Galena A.S. Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
TW450810B (en) * 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
DE19744621A1 (de) * 1997-10-09 1999-04-15 Muehlbauer Ernst Kg Mischung zur Verwendung als Wundverband
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE19802205A1 (de) * 1998-01-22 1999-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen, enthaltend erhöhte Elektrolytkonzentrationen
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
CA2326222C (en) 1998-04-27 2008-09-23 Fujisawa Pharmaceutical Co., Ltd. Medicinal compositions
GB9814640D0 (en) * 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
WO2002065947A2 (de) * 2001-02-16 2002-08-29 Abbott Laboratories Vascular Enterprises Limited Implante mit fk506 zur restenosebehandlung und -prophylaxe
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
GB0218996D0 (en) * 2002-08-14 2002-09-25 Novartis Ag Organic compounds
US20060115522A1 (en) * 2003-02-17 2006-06-01 Cipla Ltd Pharmaceutical composition
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
AU2004258745A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible formulation of an anti-inflammatory agent
RU2375044C2 (ru) * 2004-04-08 2009-12-10 Новартис Аг Пимекролимусная пенная композиция, включающая гексиленгликоль, необязательно олеиловый спирт, диметилизосорбид и/или триглицериды со средними цепями
GB0408070D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Pharmaceutical formulations
GB0508827D0 (en) * 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
WO2008063563A2 (en) 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
EP2016935A1 (en) * 2007-07-09 2009-01-21 Intendis GmbH Pharmaceutical composition for topical application of poorly soluble compounds
CN101288643B (zh) * 2008-06-17 2012-11-14 杨喜鸿 含有他克莫司的凝胶剂组合物及其制备方法和药物应用
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) * 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技(北京)有限公司 一种祛痘用皮肤外用剂
WO2013111817A1 (ja) * 2012-01-25 2013-08-01 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
EP2948134B1 (en) * 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
MX367121B (es) * 2013-08-02 2019-08-06 Laboratorio Raam De Sahuayo S A De C V Composición sólida estable de inmunosupresores.
DE102013222164A1 (de) * 2013-10-31 2015-04-30 Deb Ip Limited Stabilisierte multiple Emulsionen als Hautschutzprodukt
US10765665B2 (en) * 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途
CN109069418A (zh) * 2016-04-04 2018-12-21 药品配送方案有限公司 包含他克莫司的局部组合物
IL267869B2 (en) 2017-01-06 2023-10-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
KR101973065B1 (ko) 2017-09-13 2019-04-26 (주)썬테크 풍력 발전기 및 풍력 발전기의 블레이드 팁
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
KR101995905B1 (ko) 2018-03-27 2019-07-04 (주)썬테크 풍력 발전기 및 풍력 발전기의 발전모터
WO2019233722A1 (en) * 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
PH26083A (en) 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
JP2799208B2 (ja) 1987-12-09 1998-09-17 フアイソンズ・ピーエルシー マクロ環状化合物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
US5061700A (en) 1989-11-16 1991-10-29 Gordon Jay Dow Glyceryl acetate ointment vehicles
JPH05504956A (ja) 1990-03-12 1993-07-29 藤沢薬品工業株式会社 トリシクロ化合物
EP0533930A1 (en) 1990-06-11 1993-03-31 Fujisawa Pharmaceutical Co., Ltd. Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease
MY110418A (en) 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
ATE150304T1 (de) * 1990-09-04 1997-04-15 Fujisawa Pharmaceutical Co Tricyclische verbindungen enthaltende salben
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5252732A (en) 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
HUT66531A (en) 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
MY110603A (en) 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
DE10199039I2 (de) 1993-10-22 2008-08-07 Hexal Ag Ind 25 Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator

Similar Documents

Publication Publication Date Title
JP2012131827A5 (ja)
JP2008513467A5 (ja)
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
JP2014129360A5 (ja)
BR112015012547A2 (pt) composições de prostaciclina e métodos de sua utilização
MX2015006632A (es) Formulaciones de uso topico de tetraciclina, preparaciones y usos de las mismas.
JP2014218522A5 (ja)
JP2016510019A5 (ja)
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014014832A2 (pt) formulação e método de controlar fungos
WO2014108846A3 (en) Soothing cosmetic composition based on salicylic acid
JP2013538853A5 (ja)
TR201818761T4 (tr) 4-amino-5-floro-3-[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]-1h-kinolin-2-on laktat monohidrat içeren farmasötik bileşimler.
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
JP2012236016A5 (ja)
RS53783B1 (en) INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM
RS54131B1 (en) NEW PHARMACEUTICAL FORMULATION FOR FUNGAL INFECTION TREATMENT
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
JP2014062109A5 (ja)
JP2013253067A5 (ja)
RU2016138028A (ru) Жидкие фармацевтические суспензии, содержащие висмут
JP2016534062A5 (ja)
BR112015027436A8 (pt) composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos
FR2999934B1 (fr) Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane
CO7101241A2 (es) Formulaciones de antibióticos